| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015962003 |
| P356 | DOI | 10.1023/A:1025468611547 |
| P953 | full work available at URL | https://link.springer.com/content/pdf/10.1023/A:1025468611547.pdf |
| https://link.springer.com/article/10.1023/A:1025468611547/fulltext.html | ||
| P698 | PubMed publication ID | 14578681 |
| P2093 | author name string | Louis Denis | |
| Paul Jerabek | |||
| Charles R. Thomas | |||
| Umber Salman | |||
| Lisa A. Hammond | |||
| John G. Kuhn | |||
| P2860 | cites work | Annals of Oncology | Q326122 |
| American Journal of Physiology | Q2160146 | ||
| Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations | Q28236042 | ||
| Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus | Q28327167 | ||
| Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions | Q28375843 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| Requirement of vascular integrin alpha v beta 3 for angiogenesis | Q29619681 | ||
| Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. | Q31982942 | ||
| 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases | Q32002205 | ||
| Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. | Q32053919 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. | Q54142489 | ||
| Differential diagnosis of AH109A tumor and inflammation by radioscintigraphy with L-[methyl-11C]methionine. | Q55260820 | ||
| Uptake of 14C- and 11C-labeled glutamate, glutamine and aspartate in vitro and in vivo. | Q55475799 | ||
| Imaging the expression of transfected genes in vivo. | Q55480163 | ||
| Glucose uptake by gliomas after treatment. A positron emission tomographic study. | Q55484951 | ||
| Syntheses of the First Endothelin-A- and -B-Selective Radioligands for Positron Emission Tomography | Q56988040 | ||
| Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma | Q60652413 | ||
| Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma | Q60652414 | ||
| Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins | Q61764268 | ||
| Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil | Q61868312 | ||
| Quantitative Measurements of Prostatic Blood Flow and Blood Volume by Positron Emission Tomography | Q67463644 | ||
| Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET | Q68096475 | ||
| Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma | Q68184538 | ||
| Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone | Q68794152 | ||
| [Double tracer whole body autoradiography using a short-lived positron emitter and a long-lived beta emitter] | Q69583194 | ||
| Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody | Q69755368 | ||
| Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia | Q69785312 | ||
| In vivo lactate production and utilization by Jensen sarcoma and Morris hepatoma 7288CTC | Q69989378 | ||
| Lung tumor imaging by positron emission tomography using C-11 L-methionine | Q70077247 | ||
| Measurement of brain pH using 11CO2 and positron emission tomography | Q70463197 | ||
| Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study | Q70467422 | ||
| Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma | Q71102409 | ||
| Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging | Q71152335 | ||
| Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer | Q71197587 | ||
| Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients | Q71727525 | ||
| Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study | Q71911633 | ||
| Sigma 2 receptors as potential biomarkers of proliferation in breast cancer | Q71955607 | ||
| Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography | Q72054584 | ||
| Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation | Q72117990 | ||
| Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? | Q72240720 | ||
| Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia | Q72561939 | ||
| Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? | Q72577122 | ||
| Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET | Q72590794 | ||
| In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET | Q72616616 | ||
| Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis | Q72729798 | ||
| Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma | Q72790499 | ||
| PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates | Q73050767 | ||
| Irradiation effects on the metabolism of metastatic brain tumors: analysis by positron emission tomography and 1H-magnetic resonance spectroscopy | Q73072377 | ||
| Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose | Q73228576 | ||
| Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer | Q73274281 | ||
| 9:15-9:30. Use of a Spherical 3-D Blob Analysis Program as a Method of Determination of Standardized Uptake Value (SUV) for Following Tumor Response to Chemotherapeutic Agents (CTA) | Q73379280 | ||
| Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma | Q73442643 | ||
| PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine | Q73582898 | ||
| Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer | Q73605081 | ||
| Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium | Q73616527 | ||
| Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients | Q73648001 | ||
| Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study | Q73890263 | ||
| Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer | Q77603503 | ||
| Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors | Q78182240 | ||
| Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. | Q43755978 | ||
| Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. | Q43790743 | ||
| Thymidine phosphorylase as a target for imaging and therapy with thymine analogs | Q43836486 | ||
| Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. | Q43890708 | ||
| Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography | Q44366483 | ||
| Quantitative study in vivo of methionine cycle in humans using [methyl-2H3]- and [1-13C]methionine | Q44494347 | ||
| PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy | Q44598666 | ||
| Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey | Q45085148 | ||
| Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas | Q45152329 | ||
| Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and124iodine in patients with breast cancer | Q45204433 | ||
| Overexpression of sigma receptors in nonneural human tumors | Q45249937 | ||
| Triumph over mischance: a role for nuclear medicine in gene therapy. | Q45883044 | ||
| Problems in the use of [Me-3H]thymidine for the measurement of DNA synthesis | Q47995841 | ||
| Metabolic studies with L-[1-14C]tyrosine for the investigation of a kinetic model to measure protein synthesis rates with PET. | Q48094296 | ||
| PET-FDG of untreated and treated cerebral gliomas | Q48106385 | ||
| 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy | Q48216779 | ||
| 2-[C-11]thymidine imaging of malignant brain tumors. | Q48286386 | ||
| [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia | Q48286849 | ||
| Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors | Q48289068 | ||
| Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. | Q48289847 | ||
| In vivo imaging of oligonucleotides with positron emission tomography | Q48488864 | ||
| Measurement of regional cerebral pH in human subjects using continuous inhalation of 11CO2 and positron emission tomography | Q48629032 | ||
| Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography | Q48648666 | ||
| Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential | Q48670684 | ||
| Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine | Q48695758 | ||
| Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. | Q48697166 | ||
| Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma | Q50169529 | ||
| Substrate specificity of brain hexokinase. | Q51340833 | ||
| In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. | Q51515929 | ||
| Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. | Q52083057 | ||
| Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. | Q52241554 | ||
| Analysis of dynamic MR breast images using a model of contrast enhancement. | Q52267700 | ||
| Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. | Q32053981 | ||
| The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. | Q33606824 | ||
| PET and drug research and development | Q33686689 | ||
| Potential applications of PET imaging in developing novel cancer therapies | Q33714514 | ||
| Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase--significance for diabetes and cancer | Q33716190 | ||
| Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group | Q33837310 | ||
| Biomimetic transport and rational drug delivery | Q33918048 | ||
| Involvement of integrin alpha V gene expression in human melanoma tumorigenicity | Q34222036 | ||
| Receptor imaging in breast carcinoma: future prospects | Q34300260 | ||
| P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. | Q34308251 | ||
| Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin | Q35764323 | ||
| Sigma-2 receptors as a biomarker of proliferation in solid tumours | Q36621308 | ||
| Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data | Q36626434 | ||
| Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown | Q36753515 | ||
| Oligonucleotide analogs containing dephospho-internucleoside linkages | Q36759139 | ||
| The applications of PET in clinical oncology | Q37688431 | ||
| Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. | Q38322621 | ||
| Pharmacokinetics of [18F]FETNIM: a potential marker for PET. | Q39578429 | ||
| Hypoxia-mediated drugs for radiation and chemotherapy | Q40309193 | ||
| Pharmacokinetics of antisense oligonucleotides | Q40504539 | ||
| A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy | Q40720499 | ||
| Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. | Q40774166 | ||
| Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. | Q40800760 | ||
| Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. | Q40840451 | ||
| PET radiopharmaceuticals: state-of-the-art and future prospects | Q40846516 | ||
| Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor | Q40951781 | ||
| Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model | Q40974986 | ||
| Multitracer studies during gene therapy of hepatoma cells with herpes simplex virus thymidine kinase and ganciclovir | Q41102098 | ||
| Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy | Q41167977 | ||
| Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. | Q41195292 | ||
| Integrins, angiogenesis and vascular cell survival | Q41239257 | ||
| Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. | Q41380524 | ||
| Criteria for the tracer kinetic measurement of cerebral protein synthesis in humans with positron emission tomography | Q41435219 | ||
| Uneven distribution of protein kinase C-alpha and -beta isozymes in human sarcomas and carcinomas | Q41463332 | ||
| Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. | Q41569906 | ||
| Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. | Q41581959 | ||
| The role of positron emission tomography in pharmacokinetic analysis | Q41676775 | ||
| Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays | Q41757804 | ||
| PDGF induction of tyrosine phosphorylation of GTPase activating protein | Q41758485 | ||
| PET as a tool in the clinical evaluation of pituitary adenomas | Q41823380 | ||
| Breast cancer: PET imaging of estrogen receptors | Q42212062 | ||
| Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. | Q42467758 | ||
| Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation | Q42502434 | ||
| Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix | Q42619534 | ||
| Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method | Q43431960 | ||
| Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography | Q43561095 | ||
| Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. | Q43578058 | ||
| In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model | Q43612242 | ||
| Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer | Q43657318 | ||
| Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression | Q43694523 | ||
| In vivo labeling of endothelin receptors with [(11)C]L-753,037: studies in mice and a dog. | Q43694539 | ||
| Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas | Q43733716 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| oncology | Q162555 | ||
| positron emission tomography | Q208376 | ||
| P304 | page(s) | 309-340 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Positron emission tomography (PET): expanding the horizons of oncology drug development | |
| Positron emission tomography (PET): Expanding the horizons of oncology drug development | |||
| P478 | volume | 21 |
| Q44919843 | An image worth a thousand lives? |
| Q41174141 | Asymmetric 18F-fluorination for applications in positron emission tomography |
| Q37024077 | Endothelin receptor antagonists in cancer therapy |
| Q36768305 | Functional PET imaging in cancer drug development |
| Q37730107 | Nuclear imaging of autoimmunity: focus on IBD and RA. |
| Q36136742 | Positron emission tomography imaging of small animals in anticancer drug development |
| Q37187098 | The role of clinical imaging in oncological drug development |
Search more.